Todd B. Sherer, PhD - Publications

Michael J Fox Foundation 

54 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Dorsey ER, Wagner JD, Bull MT, Rizzieri A, Grischkan J, Achey MA, Sherer T, Chowdhury S, Meunier C, Cappelletti L, Rocker C, Richard IH, Schwarz H, Kang G, Ahmad SH, et al. Feasibility of Virtual Research Visits in Fox Trial Finder. Journal of Parkinson's Disease. 5: 505-15. PMID 26406130 DOI: 10.3233/JPD-150549  0.88
2015 Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 919-27. PMID 25737166 DOI: 10.1002/mds.26170  0.88
2015 Fuji RN, Flagella M, Baca M, Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, Katavolos P, Lee DW, Lewin-Koh SC, Lin T, Liu X, Liu S, ... ... Sherer T, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science Translational Medicine. 7: 273ra15. PMID 25653221 DOI: 10.1126/scitranslmed.aaa3634  0.88
2015 Rocker C, Cappelletti L, Marshall C, Meunier CC, Brooks DW, Sherer T, Chowdhury S. Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder. Journal of Parkinson's Disease. 5: 55-66. PMID 25624422 DOI: 10.3233/JPD-140522  0.88
2014 Choi DW, Armitage R, Brady LS, Coetzee T, Fisher W, Hyman S, Pande A, Paul S, Potter W, Roin B, Sherer T. Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs. Neuron. 84: 554-63. PMID 25442934 DOI: 10.1016/j.neuron.2014.10.027  0.88
2014 Jankovic J, Sherer T. The future of research in Parkinson disease Jama Neurology. 71: 1351-1352. PMID 25178587 DOI: 10.1001/jamaneurol.2014.1717  0.88
2014 Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC, Ahmad SO, Sunkin SM, Walker D, Cui X, Fisher DA, McCoy AM, Gamber K, Ding X, ... ... Sherer TB, et al. Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease. Neurobiology of Disease. 70: 190-203. PMID 24969022 DOI: 10.1016/j.nbd.2014.06.009  0.88
2014 Ko WK, Pioli E, Li Q, McGuire S, Dufour A, Sherer TB, Bezard E, Facheris MF. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 772-9. PMID 24610195 DOI: 10.1002/mds.25859  0.88
2013 Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, Churchill MJ, Meshul CK, Fiske BK. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. Plos One. 8: e80705. PMID 24244710 DOI: 10.1371/journal.pone.0080705  0.88
2013 Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA. A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. Disease Models & Mechanisms. 6: 1316-24. PMID 24046356 DOI: 10.1242/dmm.011940  0.88
2013 Sherer TB. Money without collaboration won't bring cures. Nature Medicine. 19: 127. PMID 23389601 DOI: 10.1038/nm0213-127  0.88
2012 Sherer TB, Chowdhury S, Peabody K, Brooks DW. Overcoming obstacles in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1606-11. PMID 23115047 DOI: 10.1002/mds.25260  0.88
2012 Frail DE, Degennaro L, Schimmer A, Kasper J, Winneker R, Sherer TB, Urkowitz A, Dave KD, Panetta J, Mccall J. Drug Repositioning Efforts by Nonprofit Foundations Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs. 389-431. DOI: 10.1002/9781118274408.ch12  0.88
2011 Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Sherer T, Frasier M, Meunier C, et al. The Parkinson Progression Marker Initiative (PPMI) Progress in Neurobiology. 95: 629-635. PMID 21930184 DOI: 10.1016/j.pneurobio.2011.09.005  0.88
2011 Sherer TB. Biomarkers for Parkinson's disease. Science Translational Medicine. 3: 79ps14. PMID 21508309 DOI: 10.1126/scitranslmed.3002488  0.88
2010 Frasier M, Chowdhury S, Eberling J, Sherer T. Biomarkers in Parkinsons disease: A funders perspective Biomarkers in Medicine. 4: 723-729. PMID 20945984 DOI: 10.2217/bmm.10.89  0.88
2009 Dorsey ER, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H. Funding of Parkinson research from industry and US federal and foundation sources. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 731-7. PMID 19133662 DOI: 10.1002/mds.22446  0.88
2008 Fiske BK, Frasier MA, Sherer TB. Special focus section: gene therapy for Parkinson's disease. Experimental Neurology. 209: 28-9. PMID 17980867 DOI: 10.1016/j.expneurol.2007.09.006  0.88
2007 Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, Greenamyre JT. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. Journal of Neurochemistry. 100: 1469-79. PMID 17241123 DOI: 10.1111/j.1471-4159.2006.04333.x  0.88
2007 Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, Miller GW. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicological Sciences : An Official Journal of the Society of Toxicology. 95: 196-204. PMID 17038483 DOI: 10.1093/toxsci/kfl133  0.88
2006 Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 136-41. PMID 16470786 DOI: 10.1002/mds.20861  0.88
2006 Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiology of Disease. 22: 404-20. PMID 16439141 DOI: 10.1016/j.nbd.2005.12.003  0.88
2005 Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. The Journal of Biological Chemistry. 280: 42026-35. PMID 16243845 DOI: 10.1074/jbc.M508628200  0.88
2005 Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicological Sciences : An Official Journal of the Society of Toxicology. 88: 193-201. PMID 16141438 DOI: 10.1093/toxsci/kfi304  0.88
2005 Sherer TB, Greenamyre JT. Oxidative damage in Parkinson's disease. Antioxidants & Redox Signaling. 7: 627-9. PMID 15890006 DOI: 10.1089/ars.2005.7.627  0.88
2005 Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Research. Molecular Brain Research. 134: 109-18. PMID 15790535 DOI: 10.1016/j.molbrainres.2004.11.007  0.88
2005 Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Experimental Neurology. 191: S17-27. PMID 15629758 DOI: 10.1016/j.expneurol.2004.08.021  0.88
2005 Sherer TB, Betarbet R, Greenamyre JT. Rotenone rat and other neurotoxin models of parkinson disease Movement Disorders. 161-172. DOI: 10.1016/B978-012088382-0/50013-X  0.88
2004 Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, Greenamyre JT, Casida JE. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chemical Research in Toxicology. 17: 1540-8. PMID 15540952 DOI: 10.1021/tx049867r  0.88
2004 Betarbet R, Poisik O, Sherer TB, Greenamyre JT. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Experimental Neurology. 187: 76-85. PMID 15081590 DOI: 10.1016/j.expneurol.2003.12.012  0.88
2004 Warren WL, Gabridge MG, Sherer T, Baile CA, Kennedy SJ. University start-up patent licensing tactics Genetic Engineering News. 24: 20+23.  0.88
2003 Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 10756-64. PMID 14645467  0.88
2003 Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism & Related Disorders. 9: S59-64. PMID 12915069 DOI: 10.1016/S1353-8020(03)00023-3  0.88
2003 Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience Letters. 341: 87-90. PMID 12686372 DOI: 10.1016/S0304-3940(03)00172-1  0.88
2003 Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Experimental Neurology. 179: 9-16. PMID 12504863 DOI: 10.1006/exnr.2002.8072  0.88
2002 Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT. Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathology (Zurich, Switzerland). 12: 499-510. PMID 12408237  0.88
2002 Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 7006-15. PMID 12177198  0.88
2002 Sherer TB, Betarbet R, Greenamyre JT. Environment, mitochondria, and Parkinson's disease. The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 8: 192-7. PMID 12061498  0.88
2002 Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 24: 308-18. PMID 11948617 DOI: 10.1002/bies.10067  0.88
2001 Sherer TB, Betarbet R, Greenamyre JT. Pesticides and Parkinson's disease. Thescientificworldjournal. 1: 207-8. PMID 12805673 DOI: 10.1100/tsw.2001.35  0.88
2001 Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. Iubmb Life. 52: 135-41. PMID 11798025 DOI: 10.1080/15216540152845939  0.88
2001 Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson's disease. Current Opinion in Investigational Drugs (London, England : 2000). 2: 657-62. PMID 11569943  0.88
2001 Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP, Tuttle JB. Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Research. 891: 94-105. PMID 11164812 DOI: 10.1016/S0006-8993(00)03203-0  0.88
2001 Greenamyre JT, Betarbet R, Sherer T, Panov A. Response: Parkinson's disease, pesticides and mitochondrial dysfunction Trends in Neurosciences. 24: 247. DOI: 10.1016/S0166-2236(00)01788-4  0.88
2000 Sherer T, Greenamyre JT. A therapeutic target and biomarker in Friedreich's ataxia. Neurology. 55: 1600-1. PMID 11113210  0.88
2000 Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience. 3: 1301-6. PMID 11100151 DOI: 10.1038/81834  0.88
2000 Sherer TB, Trimmer PA, Parks JK, Tuttle JB. Mitochondrial DNA-depleted neuroblastoma (Rho degrees) cells exhibit altered calcium signaling. Biochimica Et Biophysica Acta. 1496: 341-55. PMID 10771102 DOI: 10.1016/S0167-4889(00)00027-6  0.88
2000 Sherer TB, Clemow DB, Tuttle JB. Calcium homeostasis and nerve growth factor secretion from vascular and bladder smooth muscle cells. Cell and Tissue Research. 299: 201-11. PMID 10741461 DOI: 10.1007/s004410050018  0.88
1999 Steers WD, Clemow DB, Persson K, Sherer T, Andersson KE, Tuttl JB. Observations from the spontaneously hypertensive rat: Insight into NGF regulation and noradrenergic hyper-innervation in the lower urinary tract Advances in Experimental Medicine and Biology. 462: 283-292. PMID 10599432  0.88
1999 Sherer TB, Neff PS, Parks JK, Tuttle JB. Mitochondrial impact on nerve growth factor production in vascular smooth muscle-derived cells. Biochimica Et Biophysica Acta. 1473: 305-20. PMID 10594368 DOI: 10.1016/S0304-4165(99)00194-4  0.88
1999 Steers WD, Clemow DB, Persson K, Sherer TB, Andersson KE, Tuttle JB. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Experimental Physiology. 84: 137-47. PMID 10081714  0.88
1998 Sherer TB, Neff PS, Tuttle JB. Increased nerve growth factor mRNA stability may underlie elevated nerve growth factor secretion from hypertensive vascular smooth muscle cells. Brain Research. Molecular Brain Research. 62: 167-74. PMID 9813306 DOI: 10.1016/S0169-328X(98)00247-2  0.88
1998 Sherer TB, Neff PS, Hankins GR, Tuttle JB. Mechanisms of increased NGF production in vascular smooth muscle of the spontaneously hypertensive rat. Experimental Cell Research. 241: 186-93. PMID 9633527 DOI: 10.1006/excr.1998.4043  0.88
1997 Sherer TB, Spitsbergen JM, Steers WD, Tuttle JB. Thrombin regulates nerve growth factor secretion from vascular, but not bladder smooth muscle cells. Cell and Tissue Research. 289: 155-61. PMID 9182610 DOI: 10.1007/s004410050861  0.88
Show low-probability matches.